JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costerousse, O.
Right arrow Articles by Alhenc-Gelas, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costerousse, O.
Right arrow Articles by Alhenc-Gelas, F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ENALAPRIL MALEATE
*LOSARTAN POTASSIUM

Vol. 284, Issue 3, 1180-1187, March 1998

Angiotensin I-Converting Enzyme Inhibition but Not Angiotensin II Suppression Alters Angiotensin I-Converting Enzyme Gene Expression in Vessels and Epithelia1

Olivier Costerousse, Jacqueline Allegrini, Jean-Paul Clozel, Joël Ménard and François Alhenc-Gelas

Institut National de la Santé et de la Recherche Médicale Unité 367, Paris, France (O.C., J.A., J.M., F.A.-G.), and Pharmacology Division, Hoffmann-La Roche, Basel, Switzerland (J.-P.C.)

The concentration of angiotensin-converting enzyme (ACE) increases during chronic treatment with ACE inhibitors for unknown reasons. We investigated whether alterations in ACE mRNA and ACE concentration occur in the different tissues during ACE inhibition and the role of angiotensins in these regulations by comparing ACE inhibitors with other blockers of the renin-angiotensin system. Enalapril, an ACE inhibitor, in the range of 0.3 to 10 mg/kg/day in rats induced dose- and time-dependant increases in plasma ACE up to two to three times control values. There were significant increases in the steady state ACE mRNA in the lung (32%), duodenum (64%) and aorta (324%) and 40% to 140% increases in membrane-bound enzyme concentration in these tissues and in the heart and kidney. The ACE content of purified duodenal brush border was increased by 80%, but the enzyme and its mRNA in the testis were not altered. The angiotensin II receptor antagonist losartan at several regimens of up to 30 mg/kg twice a day for 14 days produced no change in plasma ACE level or lung ACE mRNA. The human renin inhibitor ciprokiren was tested in guinea pigs, a species sensitive to this compound. Both enalapril and cilazapril induced 2-fold increases in plasma ACE, but ciprokiren (24 mg/kg/day for 12 days) had no effect. Enalapril treatment of BN/Kat rats (lacking circulating kininogens) caused a similar increase in ACE as in other rats. This study documents a general increase in ACE gene expression and enzyme concentration in tissues during ACE inhibition, with the exception of the testis, most probably reflecting an activation of the 5', so-called somatic promoter of the ACE gene. Angiotensins are not involved in this regulation and do not seem to control ACE gene expression in normal rodents.


0022-3565/98/2843-1180$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. Nikzamir, M. Nakhjavani, A. Esteghamati, and A. Rashidi
Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition
Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1274 - 1277.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. Fleming
Signaling by the Angiotensin-Converting Enzyme
Circ. Res., April 14, 2006; 98(7): 887 - 896.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
I. Fleming, K. Kohlstedt, and R. Busse
New fACEs to the Renin-Angiotensin System
Physiology, April 1, 2005; 20(2): 91 - 95.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Kohlstedt, R. Busse, and I. Fleming
Signaling via the Angiotensin-Converting Enzyme Enhances the Expression of Cyclooxygenase-2 in Endothelial Cells
Hypertension, January 1, 2005; 45(1): 126 - 132.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. Kohlstedt, R. P. Brandes, W. Muller-Esterl, R. Busse, and I. Fleming
Angiotensin-Converting Enzyme Is Involved in Outside-In Signaling in Endothelial Cells
Circ. Res., January 9, 2004; 94(1): 60 - 67.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
P. Bardoux, D. G. Bichet, H. Martin, Y. Gallois, M. Marre, M.-F. Arthus, M. Lonergan, N. Ruel, N. Bouby, and L. Bankir
Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system
Nephrol. Dial. Transplant., March 1, 2003; 18(3): 497 - 506.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
W. Huang, F. A. Gelas, and M. J. Osborne-Pellegrin
Protection of the Arterial Internal Elastic Lamina by Inhibition of the Renin-Angiotensin System in the Rat
Circ. Res., May 4, 1998; 82(8): 879 - 890.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.